JAHA:蛋白质组学分析与新发房颤的风险

2019-03-07 xing.T 网络

由此可见,在调整年龄和性别后,研究人员确定了8种与AF事件风险相关的蛋白质;在调整AF危险因素后,2种蛋白质与AF相关。未来的研究需要重复这一研究结果,以确定这些标志物是否与AF发病机制相关,以及它们是否在临床上有助于识别未来AF的风险。

先前将蛋白质组学标记与AF事件相关的研究筛选了有限的蛋白质。近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员在参加第五次评估的弗雷明汉心脏研究后代的参与者中进行了蛋白质组学分析。

研究人员通过SOMAscan蛋白质组学分析平台测量了受试者血浆蛋白水平(n=1373)。研究人员对Cox比例风险模型使用了强有力的推论,以将每种蛋白质水平与AF事件联系起来。此外,研究人员还评估了AF相关基因位点与AF相关蛋白水平之间的关联。

该研究纳入了1885名参与者(平均年龄为55±10岁,54%占女性),他们测量了蛋白质组学特征。共有349名参与者在随访期间发生房颤(平均随访18.3年)。研究人员观察到8种蛋白质在调整年龄、性别、技术协变量和多次检验校正后与AF事件显著相关(P<0.05/1373=3.6×10-5)。在对与AF相关的临床因素进行额外调整后,ADAMTS13和B型利钠肽前体N末端仍然与AF事件风险显著相关(风险比为0.78; 95%CI为0.70-0.88和1.44; 95%CI为1.22-1.70,两者均有P<3.6×10-5)。8种蛋白质中没有一种是由先前通过全基因组关联研究确定的AF相关遗传基因位点的基因编码的。

由此可见,在调整年龄和性别后,研究人员确定了8种与AF事件风险相关的蛋白质;在调整AF危险因素后,2种蛋白质与AF相关。未来的研究需要重复这一研究结果,以确定这些标志物是否与AF发病机制相关,以及它们是否在临床上有助于识别未来AF的风险。

原始出处:

Darae Ko.et al.Proteomics Profiling and Risk of New‐Onset Atrial Fibrillation: Framingham Heart Study.JAHA.2019.https://www.ahajournals.org/doi/full/10.1161/JAHA.118.010976

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1754845, encodeId=3c621e548453f, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sun May 05 20:57:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765767, encodeId=dec41e65767e7, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue May 28 09:57:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268084, encodeId=9cde126808400, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297075, encodeId=60b4129e0752f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481384, encodeId=313b1481384c9, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362220, encodeId=ce0336222048, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Mar 07 23:28:28 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1754845, encodeId=3c621e548453f, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sun May 05 20:57:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765767, encodeId=dec41e65767e7, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue May 28 09:57:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268084, encodeId=9cde126808400, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297075, encodeId=60b4129e0752f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481384, encodeId=313b1481384c9, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362220, encodeId=ce0336222048, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Mar 07 23:28:28 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1754845, encodeId=3c621e548453f, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sun May 05 20:57:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765767, encodeId=dec41e65767e7, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue May 28 09:57:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268084, encodeId=9cde126808400, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297075, encodeId=60b4129e0752f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481384, encodeId=313b1481384c9, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362220, encodeId=ce0336222048, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Mar 07 23:28:28 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-03-09 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1754845, encodeId=3c621e548453f, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sun May 05 20:57:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765767, encodeId=dec41e65767e7, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue May 28 09:57:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268084, encodeId=9cde126808400, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297075, encodeId=60b4129e0752f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481384, encodeId=313b1481384c9, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362220, encodeId=ce0336222048, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Mar 07 23:28:28 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1754845, encodeId=3c621e548453f, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sun May 05 20:57:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765767, encodeId=dec41e65767e7, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue May 28 09:57:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268084, encodeId=9cde126808400, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297075, encodeId=60b4129e0752f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481384, encodeId=313b1481384c9, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362220, encodeId=ce0336222048, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Mar 07 23:28:28 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1754845, encodeId=3c621e548453f, content=<a href='/topic/show?id=0a1688e33b3' target=_blank style='color:#2F92EE;'>#蛋白质组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88733, encryptionId=0a1688e33b3, topicName=蛋白质组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf6736789983, createdName=jjjiang0211, createdTime=Sun May 05 20:57:00 CST 2019, time=2019-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1765767, encodeId=dec41e65767e7, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue May 28 09:57:00 CST 2019, time=2019-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268084, encodeId=9cde126808400, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297075, encodeId=60b4129e0752f, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1481384, encodeId=313b1481384c9, content=<a href='/topic/show?id=ce0258131ff' target=_blank style='color:#2F92EE;'>#新发房颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58131, encryptionId=ce0258131ff, topicName=新发房颤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=788d7780866, createdName=若水125, createdTime=Sat Mar 09 13:57:00 CST 2019, time=2019-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=362220, encodeId=ce0336222048, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Thu Mar 07 23:28:28 CST 2019, time=2019-03-07, status=1, ipAttribution=)]
    2019-03-07 orangesking

    0

相关资讯

Circulation:用于需要瓣膜置换的主动脉瓣狭窄的蛋白质组学生物标志物

这项研究提供的证据表明,5种蛋白质在AS手术前几年发生了改变,并且这种关联似乎是由并发的动脉粥样硬化所驱动的。

PLos One:骨关节炎硬化性与非硬化软骨下骨中成骨细胞分泌蛋白质组的比较

这些发现提示骨调节蛋白和fibulin-3片段可作为监测骨关节炎软骨下骨代谢早期变化的生物标志物。

Circulation:蛋白质组学生物标志物可预测需瓣膜置换的主动脉瓣狭窄

主动脉瓣狭窄(AS)是心脏瓣膜手术最常见的适应证,若不治疗死亡率非常高。目前,AS的病因学尚不清楚。既往相关人体研究通常为病例对照研究,开展前瞻性研究探寻可预测需瓣膜置换的AS生物标志物有望为我们认识AS的机制提供新见解。

中国人类蛋白质组学研究新突破三大看点

近日,生命科学研究领域再传喜讯!我国科学家通过国际权威期刊《自然》杂志上线发表了关于早期肝细胞癌蛋白质组研究领域取得突破的论文,发现了肝细胞癌精准治疗的潜在新靶点。什么是蛋白质组学?这次发现有何重大科学价值?对于接下来的临床治疗和药物研发又意味着什么?记者第一时间来到国家蛋白质科学中心·北京,采访了论文团队的科学家们。蛋白质组学:破译生命天书的“解码神器”蛋白质是遗传信息表达的“最后一公里”,

Hypertension:体位性低血压心血管标志物的蛋白质组学研究!

由此可见,OH患者的蛋白质组学分析揭示了动脉粥样硬化血栓形成和炎症的生物标志。MMP-7和TIM-1循环水平与OH独立相关,可能参与心血管疾病的进展。

Chest:血浆蛋白质组学生物标志物区分良性和恶性肺结节能力的评估

当用于pCA≤50%的肺结节患者时,综合分类法可准确识别良性肺结节并具有良好的性能特征。